Robertson J A
Law School, University of Texas, 727 Dean Keeton Street, Austin, Texas, USA.
J Med Ethics. 2003 Aug;29(4):213-6. doi: 10.1136/jme.29.4.213.
New uses of preimplantation genetic diagnosis (PGD) to screen embryos prior to transfer raise ethical, legal, and policy issues that deserve close attention. Extensions for medical purposes, such as to identify susceptibility genes, late onset disease, and human leukocyte antigen (HLA) matching, are usually ethically acceptable. Whether embryo screening for gender, perfect pitch, or other non-medical characteristics are also acceptable depends upon the parental needs served and the harm posed to embryos, children, and society. Speculations about potential future uses of PGD should not prevent otherwise acceptable current uses of PGD.
胚胎植入前基因诊断（PGD）在胚胎移植前进行筛查的新用途引发了值得密切关注的伦理、法律和政策问题。医学用途的扩展，如识别易感基因、迟发性疾病和人类白细胞抗原（HLA）匹配，通常在伦理上是可以接受的。胚胎性别、绝对音高或其他非医学特征的筛查是否也可接受，取决于所满足的父母需求以及对胚胎、儿童和社会造成的危害。对PGD未来潜在用途的猜测不应妨碍目前其他可接受的PGD用途。
